{"groups":[{"description":"Patients receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nTaselisib: Given PO","id":"FG000","title":"Treatment (Taselisib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Never started treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"44"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Alternative Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"70"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"66"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"61"}],"comment":"Four patients did not initiate protocol therapy and five patients initiated therapy but were subsequently found to be ineligible by central review. This is the primary analysis population.","type":"Eligible and Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Treatment continued until disease progression or intolerability.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"70"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For subprotocol W, patients had to have tumors with an activating PIK3CA mutation.","recruitmentDetails":"Subprotocol I was activated on February 25, 2016. 97 patients were assigned to Subprotocol I after screening, all from the screening cohort. Of the 97 patients, 70 patients enrolled in the study between March 2016 and April 2017."}